Published in J Hepatol on March 01, 2003
Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut (2005) 2.39
Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med (2014) 1.64
Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Am J Physiol Gastrointest Liver Physiol (2009) 1.17
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2016) 1.15
Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology (2010) 1.12
Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial. Gastroenterology (2011) 1.07
Management of chronic hepatitis C. Postgrad Med J (2005) 1.03
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2014) 0.99
Clinical Monitoring of Chronic Hepatitis C Based on its Natural History and Therapy. N Am J Med Sci (Boston) (2014) 0.88
Insulin resistance, steatosis, and fibrosis in Egyptian patients with chronic Hepatitis C virus infection. Saudi J Gastroenterol (2011) 0.84
Update on Alcohol and Viral Hepatitis. J Clin Transl Hepatol (2014) 0.81
Pathological evolution of hepatitis C virus-"Healthy carriers". World J Gastroenterol (2008) 0.80
Thyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspective. Endocr Pract (2013) 0.77
Factors influencing the rate of fibrosis progression in chronic hepatitis C. Dig Dis Sci (2005) 0.77
Moderate/heavy alcohol use and HCV infection among injection drug users in two Russian cities. Drug Alcohol Depend (2013) 0.77
Assessment of hepatic fibrosis in pediatric cases with hepatitis C virus in Egypt. World J Gastroenterol (2007) 0.76
Willingness to undergo a repeat liver biopsy among HIV/hepatitis C virus-coinfected and hepatitis C virus-monoinfected patients. J Clin Gastroenterol (2013) 0.75
Epidemiological Survey of Hepatitis C Virus Infection in Fife, Scotland. Gastroenterology Res (2009) 0.75
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med (2002) 7.52
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology (2007) 3.75
Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol (2007) 2.75
Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases. Am J Surg Pathol (2003) 2.71
Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med (2013) 2.68
Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost (2012) 2.61
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis (2012) 2.41
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology (2004) 2.28
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology (2010) 2.20
The impact of race/ethnicity on the clinical epidemiology of autoimmune hepatitis. J Clin Gastroenterol (2012) 2.20
Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology (2011) 2.16
Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology (2011) 2.14
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology (2002) 2.06
Human immunodeficiency virus-associated blepharoptosis. Ophthal Plast Reconstr Surg (2011) 2.03
Prevalence of methylenetetrahydrofolate reductase 677T and 1298C alleles and folate status: a comparative study in Mexican, West African, and European populations. Am J Clin Nutr (2006) 1.98
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology (2011) 1.85
A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol (2011) 1.79
Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases. FEMS Microbiol Ecol (2002) 1.75
Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. Dig Dis Sci (2010) 1.70
Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology (2006) 1.70
Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol (2004) 1.69
Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology (2013) 1.64
Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int (2008) 1.62
Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology (2011) 1.57
Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C. Clin Chem Lab Med (2012) 1.50
Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol (2004) 1.49
Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab (2010) 1.46
Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J Hepatol (2009) 1.43
Cellular and molecular abnormalities of a macronodular adrenal hyperplasia causing beta-blocker-sensitive Cushing's syndrome. Arq Bras Endocrinol Metabol (2007) 1.39
Duplication of MER115 on chromosome 4 in patients with primary biliary cirrhosis. Liver Int (2008) 1.39
The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health (2007) 1.35
The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist (2010) 1.34
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology (2003) 1.31
Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. Liver Int (2007) 1.30
Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol (2011) 1.29
Intermittent hypoxia induces early functional cardiovascular remodeling in mice. Am J Respir Crit Care Med (2007) 1.27
Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis (2010) 1.26
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology (2012) 1.19
A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol (2013) 1.15
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology (2013) 1.14
Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res (2013) 1.12
A model to predict severe HCV-related disease following liver transplantation. Hepatology (2003) 1.06
Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications. World J Gastroenterol (2012) 1.05
Chronic hepatitis B infection. Clin Liver Dis (2012) 1.05
Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol (2008) 1.05
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results. Antivir Ther (2013) 1.04
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology (2013) 1.03
Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. J Hepatol (2009) 1.02
Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. Clin Biochem (2008) 1.01
A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology (2004) 1.00
Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1alpha-mutated hepatocellular adenoma. Cancer Res (2007) 0.99
Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. Eur J Cancer (2009) 0.99
A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl (2003) 0.96
Effects of vitamin B12 and folate deficiencies on DNA methylation and carcinogenesis in rat liver. Clin Chem Lab Med (2003) 0.95
ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. J Hepatol (2013) 0.95
Significance of low levels of thyroglobulin in fine needle aspirates from cervical lymph nodes of patients with a history of differentiated thyroid cancer. Eur J Endocrinol (2008) 0.95
Features and distribution of CD8 T cells with human leukocyte antigen class I-specific receptor expression in chronic hepatitis C. Hepatology (2007) 0.94
Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis (2013) 0.93
Methyl donor deficiency impairs fatty acid oxidation through PGC-1α hypomethylation and decreased ER-α, ERR-α, and HNF-4α in the rat liver. J Hepatol (2012) 0.93
Current approaches to the treatment of early hepatocellular carcinoma. Oncologist (2010) 0.93
Vascular and cellular stress in inflammatory bowel disease: revisiting the role of homocysteine. Am J Gastroenterol (2007) 0.93
Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy. PLoS One (2012) 0.92
High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial). Gastroenterology (2011) 0.92
Immunohistochemical markers on needle biopsies are helpful for the diagnosis of focal nodular hyperplasia and hepatocellular adenoma subtypes. Am J Surg Pathol (2012) 0.91
Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C. Antimicrob Agents Chemother (2013) 0.91
Systematic analysis of G protein-coupled receptor gene expression in adrenocorticotropin-independent macronodular adrenocortical hyperplasia identifies novel targets for pharmacological control of adrenal Cushing's syndrome. J Clin Endocrinol Metab (2010) 0.90
Prevalence of renal abnormalities in chronic HBV infection: the HARPE study. Liver Int (2014) 0.90
Mild neonatal hypoxia exacerbates the effects of vitamin-deficient diet on homocysteine metabolism in rats. Pediatr Res (2005) 0.89
Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol (2009) 0.89
A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology (2002) 0.89
Immunohistochemical markers in the diagnosis of papillary thyroid carcinomas: The promising role of combined immunostaining using HBME-1 and CD56. Pathol Res Pract (2013) 0.88
Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. Cancer Biomark (2012) 0.88
Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver. Liver Int (2012) 0.88
Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail. Liver Int (2006) 0.87
Environmental influence on the worldwide prevalence of a 776C->G variant in the transcobalamin gene (TCN2). J Med Genet (2007) 0.87
Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev (2011) 0.87
Association of MTRR 66A>G polymorphism with superoxide dismutase and disease activity in patients with Crohn's disease. Am J Gastroenterol (2007) 0.87
Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery. Curr Gastroenterol Rep (2014) 0.86
Ectopic expression of the gastric inhibitory polypeptide receptor gene is a sufficient genetic event to induce benign adrenocortical tumor in a xenotransplantation model. Endocrinology (2005) 0.86
Accuracy of bilateral inferior petrosal or cavernous sinuses sampling in predicting the lateralization of Cushing's disease pituitary microadenoma: influence of catheter position and anatomy of venous drainage. J Clin Endocrinol Metab (2003) 0.86
Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. Clin Chim Acta (2009) 0.85
Very early prophylactic thyroid surgery for infants with a mutation of the RET proto-oncogene at codon 634: evaluation of the implementation of international guidelines for MEN type 2 in a single centre. Clin Endocrinol (Oxf) (2006) 0.84
Value of immunohistochemical markers in preinvasive bronchial lesions in risk assessment of lung cancer. Clin Cancer Res (2003) 0.84
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. Liver Int (2013) 0.84
Hepatocellular carcinoma surveillance: a national survey of current practices in the USA. Dig Dis Sci (2014) 0.83
A splicing variant leads to complete loss of function of betaine-homocysteine methyltransferase (BHMT) gene in hepatocellular carcinoma. Int J Biochem Cell Biol (2011) 0.83
Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. Clin Pharmacol Ther (2005) 0.83
A clinical assessment of Wilson disease in patients with concurrent liver disease. J Clin Gastroenterol (2011) 0.83
Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. J Clin Pharmacol (2005) 0.82
Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib. BMJ Case Rep (2012) 0.82
Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study. Eur J Gastroenterol Hepatol (2016) 0.81
Cellular mechanics of germ band retraction in Drosophila. Dev Biol (2013) 0.81